Business
Illustration Databricks Financing
Databricks logo (CFOTO/Future Publishing via Getty Images)
ABCDEFGHI... J

Databricks’ employees are cashing in on its Series J

Databricks is raising $10 billion to buy employees’ stock.

Jack Raines

Big news in the startup world as data-warehouse company Databricks announced a $10 billion Series J funding round yesterday that valued the company at $62 billion. Raising a Series J is a rare feat: SpaceX is one of the few other companies to hit this mark, raising its Series J in 2019.

In its press release, Databricks said that the $10 billion was expected to be non-dilutive.” Dan Primack noted in his Axios Pro Rata newsletter this morning that almost all of this $10 billion is going to buy shares from employees. My question when seeing this was, why not just go public?

If the money is just going toward buying shares from employees, couldnt Databricks accomplish the same thing through an IPO or direct listing? During an interview with Primack at the Axios AI Summit, CEO Ali Ghodsi explained why his company was holding off on going public:

This year was an election year. We wanted to get some stability — people are worried about interest rates, inflation... So we said look, its dumb to IPO this year, so were definitely going to wait.

One of the more interesting trends in the venture-backed startup market over the last few years has been IPO postponement by some of the strongest startups. Because the best-performing companies have high demand for their stock, they can create liquidity events for employees and investors through tender offers, eliminating one of the primary uses of an IPO. As I wrote two weeks ago,

However, there are two very important reasons for companies to go public: easier access to capital and liquidity for shareholders. On the first point, publicly traded companies can easily raise new funding through secondary offerings, allowing them to opportunistically strengthen their balance sheets...

But what if you’re a company with a well-capitalized balance sheet that doesn’t need outside funding? Then your only real motivation for going public is liquidity. And what if private market investors will happily buy those shares from you and your employees? Then you could… just… stay private forever?

For Databricks, the Series J makes a ton of sense. Employees can derisk their wealth by selling stock to investors, and the company can wait for a more opportune moment to go public when it might fetch an even higher valuation. Given the companys accelerating revenue growth (revenue was up 60% year on year in Q3 2024), its not unreasonable to think that its valuation will continue to climb as it approaches a potential 2025 or 2026 IPO. Investors in the Series J round certainly hope so.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.